Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen (NASDAQ: OCGN) announced the approval of stock options for 48,800 shares and restricted stock units (RSUs) covering 8,200 shares to three new employees as of October 16, 2021. The stock options, with a ten-year term, have an exercise price of $8.66 per share, equal to the closing stock price on the grant date. The options and RSUs will vest annually over three years, contingent on continued employment. This grant is made under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.
Ocugen, a biopharmaceutical company (NASDAQ: OCGN), announced that CEO Dr. Shankar Musunuri will present at the 2021 Cantor Virtual Global Healthcare Conference on September 28, 2021, at 8 a.m. ET. He will discuss the company’s investigational COVID-19 vaccine COVAXIN™, co-developed with Bharat Biotech, and its innovative modifier gene therapy platform aimed at treating retinal diseases. The presentation will be accessible live and later on Ocugen's Investor Relations page.
On September 16, 2021, Ocugen approved the grant of stock options for 137,250 shares and restricted stock units (RSUs) for 23,000 shares to seven employees as inducements for employment. The stock options have a ten-year term with an exercise price of $7.54, set at the common stock's closing price on the grant date. Both the stock options and RSUs vest over three years, contingent on the employees' continued service. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and were issued outside of Ocugen's 2019 Equity Incentive Plan.
Ocugen, a biopharmaceutical company (NASDAQ: OCGN), announced its participation in upcoming investor conferences: Citi’s 16th Annual BioPharma Virtual Conference from September 8-10, 2021, and the H.C. Wainwright Global Investment Conference from September 13-15, 2021.
Dr. Shankar Musunuri will present at Citi's conference, while CFO Sanjay Subramanian will present at H.C. Wainwright. They will discuss the co-development of COVAXIN™, a COVID-19 vaccine, and advancements in Ocugen's gene therapy platform targeting retinal diseases.
Ocugen, Inc. (NASDAQ: OCGN) announced the approval of stock options for 84,000 shares and restricted stock units (RSUs) for 14,100 shares to five new employees. These options have a ten-year term with an exercise price of $7.06 per share, effective August 16, 2021. The vesting will occur in equal annual installments over three years. This grant was made as a material inducement for employment, aligning with Nasdaq listing regulations. Ocugen is engaged in developing gene therapies for blindness diseases and COVID-19 vaccine candidates.
Ocugen reports significant progress in its pipeline with the completion of its regulatory submission for COVAXIN™ to Health Canada and ongoing FDA discussions. The company achieved a $115.8 million cash position, up from $24.2 million at year-end 2020. Major financials include research and development expenses of $18.9 million driven by a $15 million payment to Bharat Biotech, and a net loss per share of $0.13. The organization also welcomed new senior management and expanded its workforce to support growth in clinical development and commercialization.
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company, announced a conference call to discuss its Q2 2021 financial results and provide a business update on August 6, 2021, at 8:30 a.m. ET. A pre-market earnings announcement will precede the call. Investors can participate via dial-in or webcast. Ocugen focuses on developing gene therapies for blindness and a COVID-19 vaccine, notably co-developing the COVAXIN™ vaccine. The release highlights forward-looking statements and encourages reviewing risk factors in their SEC filings.
Ocugen, Inc. (NASDAQ: OCGN) announced the approval of stock options for 150,750 shares and restricted stock units (RSUs) for 25,250 shares to seven new employees as of July 16, 2021. The stock options come with a ten-year term at an exercise price of $6.66 per share, aligning with the closing price on the grant date. Both the options and RSUs will vest in equal annual installments over three years, contingent on continued service. This grant aims to incentivize new talent in line with Nasdaq Listing Rule 5635(c)(4).
Ocugen, Inc. (OCGN) announced the initiation of a rolling submission to Health Canada for COVAXIN™, its COVID-19 vaccine candidate developed in collaboration with Bharat Biotech. This decision follows positive Phase 3 clinical trial results showcasing efficacy and safety among nearly 25,800 participants. The rolling submission allows for ongoing review of data as it becomes available, potentially speeding up the approval process. COVAXIN™ has demonstrated a strong safety profile and is currently administered under emergency authorizations in 13 countries.
Ocugen reported positive Phase 3 results for COVAXIN™, a COVID-19 vaccine candidate co-developed with Bharat Biotech. The vaccine demonstrated 77.8% efficacy against symptomatic COVID-19 and 93.4% against severe cases. Additionally, efficacy against the Delta variant stands at 65.2%. Adverse events were comparable to placebo, with 12.4% of subjects reporting mild side effects and less than 0.5% serious events. Ocugen plans to submit a Biologics License Application in the U.S. and is in discussions for approval in Canada.